Are Outcomes-Based Managed Entry Agreements Dead In Europe?
Outcomes-based managed entry agreements designed to help ensure access to expensive new medicines are not sustainable and have so far failed to provide a solution to the problem of funding costly innovative drugs, according to Ad Schuurman from ZIN, the Dutch National Healthcare Institute.
You may also be interested in...
The Dutch Pharmaceutical industry association is calling for an agreement with the government to control the medicines budget and wants to start a new conversation about drug pricing.
Industry access to real world data for regulatory and market access purposes in Asia Pacific compares poorly with the US.
Draft guidelines due out for consultation this week in Italy are expected to shed more light on what companies will have to reveal during pricing and reimbursement negotiations.